Lantern Pharma Inc (LTRN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Lantern Pharma Inc (LTRN) has a cash flow conversion efficiency ratio of -0.477x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.57 Million) by net assets ($9.59 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See LTRN net asset quality index to measure how much of total assets are equity-financed.
Lantern Pharma Inc - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Lantern Pharma Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore Lantern Pharma Inc (LTRN) debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Lantern Pharma Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Lantern Pharma Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Naos Small Cap Opportunities Company Ltd
AU:NSC
|
0.063x |
|
Prodigy Public Company Limited
BK:PDG
|
0.055x |
|
Multi Hanna Kreasindo Tbk Pt
JK:MHKI
|
-0.176x |
|
TJ media Co. Ltd
KQ:032540
|
0.033x |
|
Western Alaska Minerals Corp
V:WAM
|
-0.616x |
|
Greencoat UK Wind PLC
LSE:UKW
|
0.042x |
|
Yuyu Pharma Inc
KO:000227
|
0.006x |
|
Cannindah Resources Ltd
AU:CAE
|
-0.041x |
Annual Cash Flow Conversion Efficiency for Lantern Pharma Inc (2018–2024)
The table below shows the annual cash flow conversion efficiency of Lantern Pharma Inc from 2018 to 2024. For the full company profile with market capitalisation and key ratios, see Lantern Pharma Inc stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $21.19 Million | $-17.81 Million | -0.841x | -139.73% |
| 2023-12-31 | $40.91 Million | $-14.35 Million | -0.351x | -53.93% |
| 2022-12-31 | $56.04 Million | $-12.77 Million | -0.228x | -53.96% |
| 2021-12-31 | $71.57 Million | $-10.59 Million | -0.148x | +48.42% |
| 2020-12-31 | $19.70 Million | $-5.65 Million | -0.287x | +87.28% |
| 2019-12-31 | $943.28K | $-2.13 Million | -2.256x | -135.80% |
| 2018-12-31 | $-201.80K | $-1.27 Million | 6.301x | -- |
About Lantern Pharma Inc
Lantern Pharma Inc. focuses on the discovery and development of oncology drug in India. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, as well as gliob… Read more